-
1دورية أكاديمية
المؤلفون: Greaney, Samantha K, Algazi, Alain P, Tsai, Katy K, Takamura, Kathryn T, Chen, Lawrence, Twitty, Christopher G, Zhang, Li, Paciorek, Alan, Pierce, Robert H, Le, Mai H, Daud, Adil I, Fong, Lawrence
المصدر: Cancer Immunology Research. 8(2)
مصطلحات موضوعية: Clinical Trials and Supportive Activities, Cancer, Clinical Research, Inflammatory and immune system, Adjuvants, Immunologic, Antigens, Neoplasm, Biomarkers, CD8-Positive T-Lymphocytes, Electroporation, Humans, Immunity, Cellular, Immunotherapy, Interferon-gamma, Interleukin-12, Melanoma, Neoplasm Staging, Patient Safety, Plasmids, Skin Neoplasms, Treatment Outcome, Tumor Microenvironment, Immunology, Oncology and Carcinogenesis, Pharmacology and Pharmaceutical Sciences
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/28b0z9wrTest
-
2دورية أكاديمية
المؤلفون: Nosrati, Adi1, Tsai, Katy K1, Goldinger, Simone M2, Tumeh, Paul3, Grimes, Barbara4, Loo, Kimberly1, Algazi, Alain P1, Nguyen-Kim, Thi Dan Linh5, Levesque, Mitchell2, Dummer, Reinhard2, Hamid, Omid6, Daud, Adil1
المصدر: British Journal of Cancer. 4/25/2017, Vol. 116 Issue 9, p1141-1147. 7p. 1 Diagram, 4 Charts, 1 Graph.
مصطلحات موضوعية: *MELANOMA treatment, *AGE distribution, *ANTIGENS, *COMPARATIVE studies, *GENES, *IMMUNOTHERAPY, *LACTATE dehydrogenase, *RESEARCH methodology, *MEDICAL cooperation, *MELANOMA, *MONOCLONAL antibodies, *PROGNOSIS, *RESEARCH, *TUMOR classification, *EVALUATION research
-
3دورية أكاديمية
المؤلفون: Algazi, Alain P.1 alain.algazi@ucsf.edu, Tsai, Katy K.1, Shoushtari, Alexander N.2, Munhoz, Rodrigo R.2, Eroglu, Zeynep3, Piulats, Josep M.4, Ott, Patrick A.5, Johnson, Douglas B.6, Hwang, Jimmy1, Daud, Adil I.1, Sosman, Jeffrey A.6, Carvajal, Richard D.7, Chmielowski, Bartosz8, Postow, Michael A.2, Weber, Jeffrey S.9, Sullivan, Ryan J.10
المصدر: Cancer (0008543X). Nov2016, Vol. 122 Issue 21, p3344-3353. 11p.
مصطلحات موضوعية: *UVEA, *MELANOMA treatment, *PROGRAMMED cell death 1 receptors, *CANCER immunotherapy, *HEALTH outcome assessment, *PEMBROLIZUMAB, *TUMOR treatment, *TUMORS, *THERAPEUTICS, *ANTINEOPLASTIC agents, *ANTIGENS, *CLINICAL trials, *COMPARATIVE studies, *LONGITUDINAL method, *RESEARCH methodology, *MEDICAL cooperation, *MELANOMA, *MONOCLONAL antibodies, *MUCOUS membranes, *PROGNOSIS, *RESEARCH, *SURVIVAL, *TUMOR classification, *EVALUATION research, *RETROSPECTIVE studies
-
4دورية أكاديمية
المؤلفون: Shoushtari, Alexander N., Munhoz, Rodrigo R., Kuk, Deborah, Ott, Patrick A., Johnson, Douglas B., Tsai, Katy K., Rapisuwon, Suthee, Eroglu, Zeynep, Sullivan, Ryan J., Luke, Jason J., Gangadhar, Tara C., Salama, April K. S., Clark, Varina, Burias, Clare, Puzanov, Igor, Atkins, Michael B., Algazi, Alain P., Ribas, Antoni, Wolchok, Jedd D., Postow, Michael A.
المصدر: Cancer (0008543X); Nov2016, Vol. 122 Issue 21, p3354-3362, 10p
مصطلحات موضوعية: MELANOMA treatment, PROGRAMMED cell death 1 receptors, APOPTOSIS, PEMBROLIZUMAB, CANCER immunotherapy, THERAPEUTICS, ANTINEOPLASTIC agents, ANTIGENS, BRAIN tumors, COMPARATIVE studies, LIVER tumors, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, MELANOMA, MONOCLONAL antibodies, MUCOUS membranes, PROGNOSIS, RESEARCH, RESEARCH funding, SKIN tumors, SURVIVAL, TUMOR classification, EVALUATION research, RETROSPECTIVE studies